Thursday , March 4 2021
Home / The Angry Bear / Covid 19 One Dose or Two IV

Covid 19 One Dose or Two IV

Summary:
Angrybearblog December 22,2020 “Eyeballing, the first shot looks 80-90% effective.” (Moderna) and “my guess is that the first shot was about 90% effective over this period.” (Pfizer). Angrybearblog December 24,2020 New England Journal of Medicine February 17 2021 We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%, a finding similar to the first-dose efficacy of 92.1% reported for the mRNA-1273 vaccine (Moderna).3With such a highly protective first dose, the benefits derived from a scarce supply of vaccine could be

Topics:
Robert Waldmann considers the following as important:

This could be interesting, too:

John Quiggin writes No point complaining about it, Australia will face carbon levies unless it changes course

Lars Syll writes Chicago economics — the triumph of empty formalism

Dean Baker writes To prevent the resurgence of the pandemic, can we talk about open-source research?

Dan Crawford writes Open thread Feb. 26, 2021

Angrybearblog December 22,2020 “Eyeballing, the first shot looks 80-90% effective.” (Moderna) and “my guess is that the first shot was about 90% effective over this period.” (Pfizer).

Angrybearblog December 24,2020

New England Journal of Medicine February 17 2021

We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%, a finding similar to the first-dose efficacy of 92.1% reported for the mRNA-1273 vaccine (Moderna).3

With such a highly protective first dose, the benefits derived from a scarce supply of vaccine could be maximized by deferring second doses until all priority group members are offered at least one dose.

You read it here first

Robert Waldmann
Robert J. Waldmann is a Professor of Economics at Univeristy of Rome “Tor Vergata” and received his PhD in Economics from Harvard University. Robert runs his personal blog and is an active contributor to Angrybear.

Leave a Reply

Your email address will not be published. Required fields are marked *